September 2026 Br J Cardiol 2026;33:115–8 doi:10.5837/bjc.2026.043
Brian Cunneen, Daniel O’Callaghan, Carmel O’Callaghan, Francis O’Neill, Bryan Loo, Peter Wheen, David Moore, David Mulcahy, Richard Armstrong, Vincent Maher
Introduction Coronary artery disease (CAD) remains one of the leading causes of mortality worldwide,1 accounting for nine million deaths globally in 2021.2 Numerous modifiable risk factors are associated with its development and progression, including dyslipidaemia, glycaemic control and smoking.3–9 Effective management of risk factors can reduce or even reverse the disease process.10–15 Screening for risk factors, however, is often sporadic and opportunistic in nature. Indeed, even after they are identified, gaps in treatment are common, with patients frequently falling short of updated guideline targets.16-20 It has been shown that when
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits